Selective delivery of rifampicin incorporated into poly (DL-lactic-co-glycolic) acid microspheres after phagocytotic uptake by alveolar macrophages, and the killing effect against intracellular Mycobacterium bovis Calmette-Guerin

被引:44
作者
Yoshida, Aya
Matumoto, Makoto
Hshizume, Hiroyuki
Oba, Yoshiro
Tomishige, Tatuo
Inagawa, Hiroyuki
Kohchi, Chie
Hino, Mami
Ito, Fuminori
Tomoda, Keishiro
Nakajima, Takehisa
Makino, Kimiko
Terada, Hiroshi
Hori, Hitoshi
Soma, Gen-Ichiro [1 ]
机构
[1] Tokyo Univ Sci, Ctr Drug Delivery Res, Noda, Chiba 2788510, Japan
[2] Univ Tokushima, Fac Engn, Tokushima, Tokushima 7708506, Japan
[3] Otsuka Pharmaceut Co Ltd, Microbiol Res Inst, Kawaguchi, Tokushima 7710192, Japan
[4] Tokushima Bunri Univ, Inst Hlth Sci, Tokushima, Tokushima 7708514, Japan
[5] Natl Fisheries Univ, Fac Appl Aqua Biol, Shimonoseki, Yamaguchi 7596595, Japan
[6] Tokyo Univ Sci, Fac Pharmaceut Sci, Noda, Chiba 2788510, Japan
关键词
macrophages; phagocytosis; tuberculosis; mycobacterium bovis; poly(DL-lactic-co-glycolic) acid; drug delivery systems;
D O I
10.1016/j.micinf.2006.06.004
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Macrophages and their phagocytotic abilities play a dominant role for defense against infected organisms. However, Mycobacterium tuberculosis can survive in the phagosomes of macrophages. In this study, the effective delivery of a drug and the killing effect of tubercle bacilli within macrophages were investigated utilizing the phagocytotic uptake of rifampicin (RFP) that had been incorporated into poly(DL-lactic-co-glycolic) acid (PLGA) microspheres. The microspheres were composed of PLGA that had a monomer ratio (lactic acid/glycolic acid) of either 50/50 or 75/25. They had molecular weights from 5000 to 20,000, and diameters of 1.5, 3.5, 6.2 and 8.9 mu m. The most significant factor for phagocytotic activity of macrophages was the diameter of the microspheres. By contrast, molecular weight and monomer ratio of PLGA did not influence phagocytosis. The amount of RFP delivered into cells was also investigated. RFP-PLGA microspheres composed of PLGA with a molecular weight of 20,000 and monomer ratio of 75/25 showed the highest amount of delivery (4 mu g/l x 106 cells). Fourteen days after infection, the survival rate of treated intracellular bacilli was 1% when compared with untreated cells. There was almost no killing effect of free RFP (4 or 15 mu g/ml) on intracellular bacilli. In vivo efficacy of RFP-PLGA was also examined in rats infected with M. tuberculosis Kurono. Intratracheal administration of RFP-PLGA microspheres was shown to be superior to free RFP for killing of intracellular bacilli and preventing granuloma formation in some lobes. These results suggest that phagocytotic activity could be part of a new drug delivery system that selectively targeted macrophages. (c) 2006 Elsevier SAS. All rights reserved.
引用
收藏
页码:2484 / 2491
页数:8
相关论文
共 11 条
[1]   Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages [J].
Barrow, ELW ;
Winchester, GA ;
Staas, JK ;
Quenelle, DC ;
Barrow, WW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (10) :2682-2689
[2]   Chemotherapeutic activity against murine tuberculosis of once weekly administered drugs (isoniazid and rifampicin) encapsulated in liposomes [J].
Labana, S ;
Pandey, R ;
Sharma, S ;
Khuller, GK .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2002, 20 (04) :301-304
[3]   Efficient intracellular delivery of rifampicin to alveolar macrophages using rifampicin-loaded PLGA microspheres: effects of molecular weight and composition of PLGA on release of rifampicin [J].
Makino, K ;
Nakajima, T ;
Shikamura, M ;
Ito, F ;
Ando, S ;
Kochi, C ;
Inagawa, H ;
Soma, GI ;
Terada, H .
COLLOIDS AND SURFACES B-BIOINTERFACES, 2004, 36 (01) :35-42
[4]   Liposome-based antitubercular drug therapy in a guinea pig model of tuberculosis [J].
Pandey, R ;
Sharma, S ;
Khuller, GK .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 23 (04) :414-415
[5]   Treatment of tuberculosis using a combination of sustained-release rifampin-loaded microspheres and oral dosing with isoniazid [J].
Quenelle, DC ;
Winchester, GA ;
Staas, JK ;
Barrow, ELW ;
Barrow, WW .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (06) :1637-1644
[6]   Mycobacterium tuberculosis:: Here today, and here tomorrow [J].
Russell, DG .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (08) :569-577
[7]   Residual polyvinyl alcohol associated with poly (D,L-lactide-co-glycolide) nanoparticles affects their physical properties and cellular uptake [J].
Sahoo, SK ;
Panyam, J ;
Prabha, S ;
Labhasetwar, V .
JOURNAL OF CONTROLLED RELEASE, 2002, 82 (01) :105-114
[8]   Inhalable microparticles containing drug combinations to target alveolar macrophages for treatment of pulmonary tuberculosis [J].
Sharma, R ;
Saxena, D ;
Dwivedi, AK ;
Misra, A .
PHARMACEUTICAL RESEARCH, 2001, 18 (10) :1405-1410
[9]   Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: Screening in an infectious disease model [J].
Suarez, S ;
O'Hara, P ;
Kazantseva, M ;
Newcomer, CE ;
Hopfer, R ;
McMurray, DN ;
Hickey, AJ .
PHARMACEUTICAL RESEARCH, 2001, 18 (09) :1315-1319
[10]  
Teo SK, 1999, INT J TUBERC LUNG D, V3, P126